HIV New Product Introduction Toolkit

CHAI has developed two new posters to support the introduction of pediatric Abacavir/Lamivudine/Dolutegravir (pALD) in health systems....

The second edition of CHAI’s HIV Market Impact Memo highlights the ongoing impact of cuts to HIV services across low- and middle-income...

This is a special edition of the CHAI HIV Market Impact Memo , a brief highlighting the significant risks facing global HIV markets and...

Last Updated: January 2025 A Stringent Regulatory Authority (SRA) is a medicines regulatory authority that enforces and ensures medicines...

CHAI is pleased to release the fifteenth issue of our annual HIV market report. The 2024 HIV Market Report provides a detailed look at...

Last updated: October 2024 Within the ARV market, there are a number of reference price lists to help inform the latest costs of adult...

Introducing the eighth edition of CHAI’s HIV Mid-Year Market Memo, a brief that covers the latest trends in the HIV space in low- and...

This tool was developed to support national HIV programs and ministries of health to estimate and compare the cost of the following two...

These Community Advisory Board (CAB) case studies capture highlights of what CAB members considered to be some of the most impactful...

This slide deck, presented by CHAI at IPHASA 2023, outlines planning considerations for the introduction of pALD throughout all stages of...

The CHAI Simple Tool is a morbidity-based forecasting tool that quantifies ARV needs over a three year period for an HIV/AIDS treatment...

CHAI is pleased to release the fourteenth issue of our annual HIV market report. This report provides a detailed look at the complex,...

This treatment optimization roadmap is a resource for Ministries of Health and partner organizations. It offers a summary of pediatric...

This document is meant to answer some of the most common questions that surround pediatric darunavir/ritonavir 120/20mg (pDRV/r) - a new...

This product profile provides a clinical overview of the best-in-class protease inhibitor (PI) formulated in a fixed-dose combination...

Introducing the seventh edition of CHAI’s HIV Mid-Year Market Memo, a brief that covers the latest trends in the HIV space in low- and...

This document is meant to answer some of the most common questions surround the fixed-dose combination of pediatric...

This case study, developed by the Optimal CAB in Malawi with support from CHAI, outlines the efforts undertaken by Malawi CAB members to...

This product profile provides a clinical overview of the fixed-dose combination of pediatric abacavir/lamivudine/ dolutegravir 60/30/5 mg...

The GAP-f pDTG task team has developed a brief outlining product introduction and rollout considerations for national programmes when...